Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes plc (ALKS)
:ALKS
Earnings Data
Report Date
Apr 23, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.29Last Year’s EPS
0.43Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 12, 2025
|% Change Since: 10.51%
|Next Earnings Date:Apr 23, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance in 2024 with record revenues, significant progress in pipeline development, and strategic debt management. However, challenges such as anticipated reductions in manufacturing and royalty revenues and the need for continued growth in mature product lines present headwinds. The company's strategic focus on profitability and pipeline advancement, particularly with ALKS 2680, positions it well for future growth.Company Guidance
During the Alkermes Fourth Quarter 2024 Financial Results Conference Call, the company provided guidance for 2025, highlighting key financial expectations and strategic focuses. In 2024, Alkermes achieved over $1.5 billion in revenue, driven by its proprietary commercial portfolio, resulting in more than $450 million in EBITDA. For 2025, the company anticipates generating over $200 million in EBITDA while advancing its orexin program. The guidance outlines total revenues for 2025 to be between $1.34 billion and $1.43 billion, with net sales from proprietary products expected to range from $1.09 billion to $1.15 billion. They forecast EBITDA between $215 million and $245 million and adjusted EBITDA from $310 million to $340 million. The focus for 2025 includes continued growth for key products like LYBALVI, with anticipated 25% demand growth, and advancing its pipeline, particularly the ALKS 2680 Phase 2 studies in narcolepsy.Record-Breaking Revenue Achievement
Alkermes achieved over $1.5 billion in revenue for 2024, driven by a proprietary product portfolio with an 18% year-over-year growth, and over $1 billion in net sales from proprietary products.
Strong EBITDA Performance
The company exceeded their EBITDA goal with more than $450 million from continuing operations and projects over $200 million in EBITDA for 2025.
Debt-Free Status and Cash Reserves
Alkermes retired all of its debt, ending 2024 with $825 million in cash. They also repurchased approximately 8 million shares, strengthening the balance sheet.
VIVITROL and LYBALVI Growth
VIVITROL sales increased by 14% year-over-year and LYBALVI by 46%. LYBALVI's growth is attributed to a 39% increase in TRx growth, with plans to expand market access in 2025.
Pipeline Progress with ALKS 2680
Significant progress in neuroscience development pipeline with two well-powered Phase 2 studies for ALKS 2680 in narcolepsy, positioning for potential transformation in 2025.
---
ALKS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALKS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 12, 2025 | $31.96 | $33.50 | +4.82% |
| Oct 24, 2024 | $27.85 | $26.85 | -3.59% |
| Jul 24, 2024 | $25.00 | $26.51 | +6.04% |
| May 01, 2024 | $24.54 | $24.01 | -2.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Alkermes plc (ALKS) report earnings?
Alkermes plc (ALKS) is schdueled to report earning on Apr 23, 2025, TBA Not Confirmed.
What is Alkermes plc (ALKS) earnings time?
Alkermes plc (ALKS) earnings time is at Apr 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALKS EPS forecast?
ALKS EPS forecast for the fiscal quarter 2025 (Q1) is 0.29.
---